Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. (FDMT) on January 22, 2026. The filing discloses unregistered sales of equity securities involving the exchange of common stock for pre-funded warrants with specific institutional investors.
Key Financial Metrics and Capital Structure
The filing details a capital restructuring event rather than operational financial performance. Key metrics include:
- Shares Exchanged: 4,850,000 shares exchanged by RA Capital Healthcare Fund, L.P. and 1,750,000 shares exchanged by Biotechnology Value Fund, L.P. (BVF) and affiliates.
- Pre-Funded Warrants Issued: 6,600,000 total pre-funded warrants issued in exchange for the common stock.
- Exercise Price: $0.0001 per share.
- Outstanding Shares (Post-Exchange): 51,007,874 shares as of January 23, 2026.
- Potential Dilution: 16,935,665 shares of common stock are issuable upon the exercise of outstanding pre-funded warrants as of January 23, 2026.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes Versus Prior Period
The primary material change is the reduction of outstanding common stock by 6,600,000 shares, which were converted into pre-funded warrants. This transaction alters the company's capital structure by creating a significant pool of immediately exercisable warrants subject to beneficial ownership limitations.
Guidance, Outlook, and Risks
Management Commentary: The Company issued the pre-funded warrants without registration in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933.
Risks and Contingencies:
- Beneficial Ownership Blocker: Holders cannot exercise the warrants if doing so would cause their aggregate beneficial ownership to exceed 4.99% or 9.99% of the total issued and outstanding shares.
- Dilution Risk: The existence of 16,935,665 shares issuable upon exercise represents potential future dilution to existing shareholders.
The filing text does not provide guidance, outlook, or commentary on unusual items beyond the described exchange.
Investor Verification Checklist
- Verify the current market price of FDMT common stock relative to the $0.0001 exercise price of the new warrants.
- Confirm the total number of shares outstanding including the 16,935,665 shares underlying outstanding pre-funded warrants.
- Review the specific beneficial ownership percentages of RA Capital and BVF to determine if the 4.99% or 9.99% blocker is currently active.
- Check subsequent filings for any cash proceeds or additional terms related to the warrant exercise.